Loading
companiesCompany
Jubilant Therapeutics
Jubilant Therapeutics, part of India's Jubilant group, designs small molecules that hit two epigenetic targets at once; JBI-802 inhibits both LSD1 and HDAC6 for myeloproliferative neoplasms and small cell lung cancer.
Also called: Jubilant Therapeutics Inc.
Overview
Jubilant Therapeutics is a precision-medicine subsidiary of Jubilant Pharmova that uses structure-based design to make dual-action small molecules. JBI-802 is an oral inhibitor of the epigenetic enzymes LSD1 and HDAC6 in a single molecule, in phase 1/2 trials in essential thrombocythaemia, other myeloproliferative neoplasms and neuroendocrine cancers including small cell lung cancer. Its pipeline also includes a PAD4 inhibitor and PD-L1 small molecules.
Headquarters
Bedminster, New Jersey, US
Scorecard
All companies#463of 1244 companies, score 6
- phase 1/2 +1
- modalities +2
- registry trials +3
0 approved, 0 in phase 3, 1 earlier, 0 targets, 3 registry studies. Formula on the scorecards page.
Type
Website
Phase 2Small-molecule inhibitor
JBI-802 is a small-molecule inhibitor from Jubilant Therapeutics Inc., in registered phase 2 trials for myeloproliferative neoplasms, chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms.